MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF DABRAFENIB PLUS TRAMETINIB VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC BRAF V600 MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Tai, T. A. [1 ]
Perampaladas, K. [2 ]
Cooney, P. [1 ]
Mensah, L. [2 ]
Jameson, K. [2 ]
Rafia, R. [2 ]
Bains, R. [2 ]
Kane, N. [2 ]
机构：
[1] Novartis Global Serv Ctr, Dublin, Ireland
[2] Novartis Pharmaceut, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT35
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [41] Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P plus C) in advanced non-small cell lung cancer (NSCLC).
    Sehgal, Kartik
    Gill, Ritu R.
    Bindal, Poorva
    Koshy, Anita Geevarghese
    McDonald, Danielle C.
    Rangachari, Deepa
    Costa, Daniel Botelho
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer (JVDF)
    Herbst, R.
    Arkenau, H.
    Bendell, J.
    Arrowsmith, E.
    Wermke, M.
    Soriano, A.
    Penel, N.
    Santana-Davila, R.
    Bischoff, H.
    Chau, I.
    Chao, B.
    Ferry, D.
    Mi, G.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S307 - S307
  • [43] Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
    Smith, Sarah
    de Almeida, Fernando Albuquerque
    Ines, Monica
    Iadeluca, Laura
    Cooper, Miranda
    VALUE IN HEALTH, 2023, 26 (01) : 64 - 70
  • [44] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
    Meng, Pei
    Koopman, Bart
    Kok, Klaas
    ter Elst, Arja
    Schuuring, Ed
    van Kempen, Leon C.
    Timens, Wim
    Hiltermann, T. Jeroen N.
    Groen, Harry J. M.
    van den Berg, Anke
    van der Wekken, Anthonie J.
    LUNG CANCER, 2020, 146 : 358 - 361
  • [46] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
  • [47] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISONS (MAIC) OF THE EFFECT OF LORLATINIB VERSUS CHEMOTHERAPY ON OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) FOR PATIENTS WITH SECOND-LINE OR LATER ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Smith, S.
    Albuquerque de Almeida, F.
    Ines, M.
    Iadeluca, L.
    Cooper, M.
    VALUE IN HEALTH, 2020, 23 : S421 - S422
  • [48] VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Hatswell, A.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    McLean, T.
    Alexopoulos, S.
    Baijal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S21 - S22
  • [49] CDK4 copy number gain in BRAF V600E-mutated non-small cell lung cancers resistant to dabrafenib plus trametinib.
    Hirai, Noriko
    Sasaki, Takaaki
    Chiba, Shinichi
    Uno, Yuji
    Takei, Hidehiro
    CANCER RESEARCH, 2021, 81 (13)
  • [50] TEPOTINIB VERSUS CHEMOTHERAPY IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC): REAL-WORLD EVIDENCE (RWE) AND MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) TO EXPLORE THE IMPACT OF SUBSEQUENT THERAPY
    Wheat, H.
    Hatswell, A.
    Christopoulos, P.
    Ekman, S.
    Guisier, F.
    Hook, E.
    Vioix, H.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
12345